Home > Business Segment > Formulation > Branded Priscription Drugs > Cardia > Biguanides + Sulphonylureas > Metmore GP1

Metmore GP1

It contains three oral anti-hyperglycaemic drugs glimepiride, pioglitazone hydrochloride and metformin hydrochloride sustained release.

The primary mechanism of action of glimepiride in lowering blood glucose appears to be dependent on stimulating the release of insulin from functioning pancreatic beta cells. Pioglitazone hydrochloride is a potent and highly selective agonist for peroxisome proliferatoractivated receptor-gamma (PPAR-γ).

Available in Metformin 500 mg Sustained Release + Pioglitazone 15 mg Glimepiride 1mg tablets (METMORE-GP 1) and Metformin 500 mg Sustained Release + Pioglitazone 15 mg Glimepiride 2 mg tablets (METMORE-GP 2).

SKU Detail

Brand Strength COMPOSITION Therapeutic Class  Type Size
METMORE -GP 1 1 mg + 500 mg + 15 mg Glimepride 1 mg + Metformin 500 mg S.R. + Pioglitazone 15 mg DIABETES Blister 10's
METMORE GP2 2 mg +500 mg+15 mg Metformin Sustained Release 500 mg + Glimepiride 2 mg +  Pioglitazone 15 mg DIABETES Blister 10's